Search tips
Search criteria 


Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
Circulation. Author manuscript; available in PMC 2010 October 27.
Published in final edited form as:
PMCID: PMC2964596

Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography

The Ludwigshafen Risk and Cardiovascular Health Study



The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is still open to debate. In the ILLUMINATE trial inhibition of CETP in patients with high cardiovascular risk was associated with increased high density lipoprotein levels but increased risk of cardiovascular morbidity and mortality. Here, we present a prospective observational study of patients referred to coronary angiography in which CETP was examined in relation to morbidity and mortality.

Methods and Results

CETP concentration was determined in 3256 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study who were referred to coronary angiography at baseline between 1997 and 2000. Median follow-up time was 7.75 years. Primary and secondary endpoints were cardiovascular and all-cause mortality, respectively. CETP levels were higher in women and lower in smokers, in diabetic patients, and in patients with unstable coronary artery disease (CAD), respectively. In addition, CETP levels were correlated negatively with high-sensitivity C-reactive protein and IL-6. After adjustment for age, sex, medication, CAD status, cardiovascular risk factors, and diabetes mellitus, the hazard ratio for death in the lowest CETP quartile was 1.33 (1.07-1.65, p=0.011) compared to patients in the highest CETP quartile. Corresponding hazard ratios for death in the second and third CETP quartile were 1.17 (0.92-1.48, p=0.19) and 1.10 (0.86-1.39, p=0.46), respectively.


We interpret our data to suggest that low endogenous CETP plasma levels per se are associated with increased cardiovascular and all-cause mortality challenging the rationale of pharmacological CETP inhibition.

Keywords: atherosclerosis, lipoproteins, mortality, coronary disease, risk factors

Cholesteryl ester transfer protein (CETP) is a key player in the metabolic interaction between high-density lipoprotein (HDL) particles and triglyceride-rich lipoproteins with its main function to redistribute between lipoproteins the core lipids cholesteryl esters and triglycerides.1 CETP was considered a potential therapeutic target when rodents known to exhibit high levels of HDL and resistance to diet-induced atherosclerosis were found to lack plasma CETP activity. However, evidence supporting the potential benefit of CETP inhibition to prevent atherosclerosis is not straightforward.2 In rabbits, CETP inhibition reduced atherosclerosis, but studies in patients with CETP mutations as well as studies in transgenic mice were inconsistent. Pilot studies employing CETP inhibitors showed promising effects on lipids with highly elevated HDL-cholesterol and reduced LDL-cholesterol levels without serious adverse effects 3, 4 However, a large, randomized, double-blind phase III clinical trial with the CETP inhibitor torcetrapib (ILLUMINATE) revealed that the increase in HDL-cholesterol in the active treatment group was associated with an increased risk of cardiovascular events and death causing premature termination of the trial. 5 It was speculated by the authors that the observed adverse clinical result may have been due to an off-target increase in blood pressure by torcetrapib, but CETP inhibition per se could not be excluded as cause. Thus, HDL-directed pharmacological intervention involving CETP has become the focus of debate.6-8 In the present study we investigated the role of CETP in atherosclerosis further by relating endogenous CETP plasma levels to CAD and mortality in the cohort of the LURIC study, a prospective observational study of patients at intermediate to high cardiovascular risk. 9


Study Design and Participants

We studied participants of the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study.9 Inclusion criteria were: German ancestry, clinical stability except for acute coronary syndromes, and the availability of a coronary angiogram. The indications for angiography in individuals in clinically stable condition were chest pain and/or noninvasive test results consistent with myocardial ischemia. Individuals suffering from acute illness other than acute coronary syndromes, chronic noncardiac diseases, or malignancy within the past 5 years and subjects unable to understand the purpose of the study were excluded. The study was approved by the Ethics Committee at the “Aerztekammer Rheinland-Pfalz”. Informed written consent was obtained from all participants.

Coronary artery disease (CAD) was assessed by angiography with maximum luminal narrowing estimated by visual analysis. Clinically relevant CAD was defined as the occurrence of ≥1 stenosis of ≥20% in ≥1 of 15 coronary segments. Individuals with stenoses <20% were considered as not having CAD.

Diabetes mellitus was diagnosed when plasma glucose was >1.25 g/L in the fasting state or >2.00 g/L 2 h after an oral glucose load10, or when antidiabetic medical treatment was prescribed. Hypertension was diagnosed when the systolic and/or diastolic blood pressure exceeded 140 and/or 90 mm Hg, respectively, or when a patient was on antihypertensive medication.

Data of CETP plasma concentration, plasma lipids and lipoprotein parameters, as well as coronary angiograms were complete in all 3256 individuals included in this study. Information on vital status was obtained from local registries. No patient was lost during follow-up. Of the 3256 persons studied, 754 deaths (23.2%) occurred during a median follow-up of 7.75 years. Cardiovascular death included sudden death, fatal myocardial infarction, death due to congestive heart failure, death immediately following intervention to treat CAD, fatal stroke, and other causes of death due to CAD. Cause of death of 24 individuals was unknown. These patients were included in calculations concerning all-cause mortality (n=754), but not in calculations considering different causes of death (n=730).

Laboratory Procedures

To perform all analyses fasting blood samples were collected prior to angiography. The standard laboratory methods have been described.9

CETP was determined using an enzyme linked immunosorbent assay (ELISA) employing a CETP-specific recombinant single-chain antibody as coating antibody and an affinity-purified polyclonal anti-CETP antibody as detection antibody, respectively.11, 12

Statistical Analysis

Data normally distributed are presented as mean ± SD. CETP, triglycerides, adiponectin, IL-6, and CRP exhibited a skewed distribution and are presented as median and (Q1-to-Q3). Data not normally distributed were transformed logarithmically for statistical analyses. Age and sex adjusted differences between subjects with and without CAD were calculated using linear or logistic regression. The effects of cardiovascular risk factors, CAD-status, intake of lipid-lowering drugs, and markers of inflammation on CETP levels were determined using general linear models entering CETP as the dependent variable and sex, age, intake of lipid-lowering drugs, CAD-status, body mass index (BMI), diabetes mellitus, metabolic syndrome, hypertension (blood pressure > 140/90 mmHg), smoking history (never, former, current), LDL-cholesterol, HDL-cholesterol, and triglycerides as covariates. LDL-cholesterol, HDL-cholesterol, LDL/HDL-ratio, triglycerides, homocysteine, adiponectin, and interleukin-6 were categorized in quartiles. Cox proportional hazard models were used to examine the effect of CETP on mortality. Multivariable adjustment was performed for age, sex, intake of lipid lowering drugs, CAD-status [none, stable CAD, unstable CAD, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)], BMI, hypertension, smoking status, LDL-cholesterol, HDL-cholesterol, triglycerides, and metabolic syndrome / type 2 diabetes mellitus.

We evaluated the combined role of CETP and inflammation markers as predictors of the risk of mortality using a likelihood-ratio test to determine whether logistic-regression models that included measurements of CETP and markers of inflammation provided a significantly better fit than did logistic-regression models limited to markers of inflammation alone. Additionally, we computed the area under receiver-operating-characteristic curves for prediction models based on different combinations of established risk factors, inflammatory markers and CETP, respectively. All statistical tests were 2-sided; P<0.05 was considered significant. The SPSS 16.0 statistical package (SPSS Inc.) was used.


Study participants

Clinical and biochemical characteristics of the study population are shown in Table 1. Besides BMI all cardiovascular risk factors were more prevalent or severe in CAD patients. At baseline CETP-levels were lower in CAD patients compared to patients without CAD (p=0.002).

Table 1
Clinical and biochemical characteristics of study participants at baseline

Association of CETP with cardiovascular risk factors and markers of inflammation

CETP plasma concentration was significantly higher in women compared to men (Table 2). Lower CETP was found in diabetic but not in metabolic syndrome patients. CETP was positively related to LDL-cholesterol and lower in patients using lipid-lowering drugs. An even stronger association was observed for the LDL/HDL ratio with a 21.2 % higher CETP in the fourth quartile (p<0.0001). No associations were found with age, body mass index, hypertension, and triglycerides. Additionally, CETP was lower in smokers and patients with unstable CAD. CETP showed a negative correlation with hsCRP and IL-6 and a positive one with homocysteine and adiponectin (Table 3).

Table 2
Association of cardiovascular risk factors with CETP
Table 3
Association of markers of inflammation with CETP

CETP and mortality from all causes

Among the 3256 persons studied, 754 deaths (23.2%) occurred during a median follow-up of 7.75 years. Compared to patients in the highest CETP quartile, the age and sex-adjusted hazard ratio for death in the lowest quartile was 1.37 (95%CI 1.10-1.70) (Table 4, Figure 1, upper left-hand panel). CETP retained prognostic value after further adjustment for intake of antihypertensive, lipid lowering and antiplatelet therapy, CAD status, cardiovascular risk factors, and diabetes mellitus with a hazard ratio of 1.33 (95%CI 1.07-1.65) in the lowest CETP quartile (Table 4, model 2). Subgroup analysis in 2560 subjects with angiographic CAD at baseline showed similar hazard ratios. No association to mortality was found for lipoprotein characteristics including LDL-cholesterol, HDL-cholesterol and triglycerides (Table 5).

Figure 1
Survival functions regarding all-cause (upper half) and cardiovascular mortality (lower half) according to quartiles of CETP in all individuals (left side) or in patients with angiographic CAD (right side). Curves were estimated within a proportional ...
Table 4
Hazard ratios for death from all causes according to CETP
Table 5
Hazard ratios for death from all causes according to various risk factors

CETP and mortality from cardiovascular causes

Among the 3256 subjects studied, 474 (15.5%) died from cardiovascular causes, 57 (1.8%) died from infection, 95 (2.9%) from cancer, and 104 (3.2%) from miscellaneous causes. Compared to patients in the highest CETP quartile, the age and sex-adjusted hazard ratio for death from cardiovascular causes was 1.38 (1.05-1.82, p=0.021) in the lowest CETP quartile, 1.19 (0.88-1.61, p=0.25) in the second, and 1.20 (0.89-1.62, p=0.23) in the third CETP quartile and, thus, similar to those obtained for mortality from all causes (Table 6 and Figure 1). Further adjustment for additional cardiovascular risk factors and inflammatory markers had only minor influence on the hazard ratios (Table 7). Again, subgroup analysis in subjects with angiographic CAD showed similar results (Table 7).

Table 6
Proportional hazards models based c-statistic for death from all causes according to different models including traditional risk factors, CETP and inflammatory markers
Table 7
Hazard ratios for cardiovascular death according to CETP

CETP and inflammatory markers

There were strong risk gradients for inflammatory markers, such as hsCRP and interleukin-6. The adjusted hazard ratios of death from all causes in the highest hsCRP and interleukin-6 quartiles were 2.05 (1.60-2.60), and 2.65 (1.95-3.56), respectively. In order to dissect the effect of CETP from that of inflammatory markers, we performed additional analysis regarding hazard ratios for death according to CETP. The association between CETP and mortality retained even after adjustment for inflammatory markers including hsCRP, IL-6, homocysteine and adiponectin with a hazard ratio of 1.31 (1.05 - 1.64) in the lowest CETP quartile (Table 4, model 3). Additionally, we computed the area under the receiver-operating-characteristic (ROC) curves including CETP and inflammatory markers (Table 6). In these ROC analyses the basic model including established risk factors yielded an area under the curve (AUC) of 0.749. Addition of inflammatory markers or CETP led to slight but not significant increase of the AUC. However, inclusion of both, inflammatory markers and CETP, to the basic model increased the AUC significantly (0.775 vs. 0.749, p=0.045).


Early observations in Japanese subjects in whom CETP deficiency was associated with very high HDL-cholesterol levels gave rise to the development of compounds inhibiting the function of CETP. However, evidence for CETP deficiency to confer protection against atherosclerosis in humans is conflicting.2 Results from different animal models are also inconsistent. Ultimately, CETP inhibition per se, and HDL-directed pharmacological interventions in general have come under closer scrutiny, as it became evident that raising HDL-cholesterol is not necessarily associated with a favourable cardiovascular outcome. 5, 7, 8

A recent meta-analysis investigated the relationship of CETP-polymorphisms with plasma lipid levels and coronary outcomes.13 Some common CETP genotypes were found to be associated with lower CETP mass and activity by 5 to 10% and with increased HDL-cholesterol by 3 to 5%. However, no or only weak associations were found between CETP genotypes and coronary outcome.13 One explanation may be the fact that common genotypes are only modestly associated with CETP concentrations. In the study presented herein with the LURIC population, we also failed to find associations between CETP TaqI genotypes and cardiovascular or all-cause mortality (data not shown). However, measurement of CETP mass indeed allowed to uncover this relationship. Direct measurement of CETP mass, known to be strongly correlated to CETP activity, 11 appears to be more informative than the use of single CETP polymorphisms. Using measurements of CETP mass, we found low CETP plasma levels to be an independent risk factor for cardiovascular events and death. This finding supports and extends the results of the ILLUMINATE study5, and challenges the rationale of pharmacological CETP inhibition. Much effort has been put in raising HDL cholesterol for cardioprotection.2 However, raising HDL-cholesterol levels solely may not be sufficient for achieving this goal, when it comes at the cost of a decreased HDL-function and, thus, of reduced reverse cholesterol transport.8, 14 The transport of peripheral cholesterol back to the liver for excretion relies on functional HDL and LDL particles, and may be hampered by low CETP levels. Results from ILLUMINATE and our study may contribute to a paradigm change shifting the focus from plasma concentrations of HDL and LDL particles to their function. In the study presented high LDL-cholesterol and low HDL-cholesterol levels and even more so a high LDL/HDL ratio were associated with high CETP concentrations suggesting an enhanced cholesterol transfer from HDL to LDL particles in the presence of high CETP. This lipoprotein pattern, considered widely undesirable, may – in the presence of high CETP levels – indicate an enhanced reverse cholesterol transport. Consequently, the therapeutic goal for future therapies may change from mere HDL elevation to the enhancement of reverse cholesterol transport.8

The relationship between plasma levels of CETP and HDL-cholesterol in our study was rather modest. The triglyceride levels in patients and controls were within normal range for most patients, while the association of CETP and HDL-cholesterol is found more clearly in hypertriglyceridemia and in the postprandial state 15.

Participants of the LURIC study represent a population at intermediate to high cardiovascular risk since patients were recruited prior to coronary angiography. Thus, our data can not necessarily be extrapolated to the general population. An increased rate of CAD and death observed in our study subjects may be due to lower CETP concentrations at baseline in men, current smokers, diabetics, patients with myocardial infarction, and patients on lipid lowering drugs, all likely to have increased risk of death and CAD during a subsequent follow-up. Therefore, we adjusted for these potential confounders and continued to find an increased hazard ratio for death in the lowest CETP quartile. Furthermore, contribution of CETP to risk prediction persisted after adjustment for inflammatory markers. On closer examination, major effects were seen in quartiles 1 and 4 with only minor differences between quartiles 2 and 3 pointing to a non-linear sigmoid shape of relationship. Additionally, in subgroup analyses we observed similar or even stronger associations in women, patients not taking lipid-lowering drugs, persons who had not experienced myocardial infarction, or non-smokers. In patients with low CETP plasma levels, we observed an increase not only of cardiovascular, but also of all-cause mortality. Interestingly, an increased rate of death from non-cardiovascular causes was observed in the active treatment group of the ILLUMINATE study, suggesting perhaps additional functions of HDL particles by mechanisms extending beyond cholesterol transport. Among others, HDL particles have antioxidant and antithrombotic properties and they are important for various functions of the vascular endothelium. 16 In addition, HDL may turn out to be a component of the immune system as a large number of HDL associated proteins have been identified to be involved in innate immunity, complement regulation, and inflammation.8 Accordingly, human CETP in vitro enhanced the lipopolysaccharide binding to plasma high-density lipoproteins. Also, the expression of the HDL-receptor SR-BI was demonstrated to protect mice against endotoxemia.17, 18

To explore whether CETP added any predictive value to a fully adjusted model with markers of inflammation, we computed ROC curves including CETP and markers of inflammation. In these analyses, the use of CETP in addition to established risk factors did not significantly affect the outcome of ROC analysis. However, concomitant use of CETP and inflammatory markers significantly improved the basic model with established risk factors alone. In addition to c-statistics, likelihood-ratio tests were used to compare the fit of a predictive model based on known risk factors including markers of inflammation to a fit of the same model after addition of CETP. In these analyses, CETP increased the usefulness of the fully adjusted model including adiponectin, hsCRP and IL-6 in prediction of risk (p<0.0001). Additionally, looking on hazard ratios for other risk factors including lipoprotein parameters and markers of inflammation, no effect was found for LDL-cholesterol, HDL-cholesterol and triglycerides, whereas, markers of inflammation exhibited significant effects on relative risk for all-cause mortality in our population. However, the association between CETP and mortality persisted even after adjustment for inflammatory markers including hsCRP, IL-6, homocysteine and adiponectin. Taken together, our data support the view that CETP may be important for the anti-inflammatory function of HDL particles and/or may have additional lipoprotein-independent functions within the immune system.

Since the detection of CETP, its role in atherogenesis has been debated extensively but remains elusive. 5, 19-21 The increased mortality in the ILLUMINATE study may - at least in part - have been due to off-target effects of the CETP inhibitor torcetrapib, as systolic blood pressure and aldosterone levels were increased in the treatment group. However, the relationship between changes in blood pressure and clinical outcome in the torcetrapib group was somehow inconsistent internally, insofar as the apparent increased risk of death was found in patients whose increase in systolic blood pressure was lower than the median. In our study we found significantly increased hazard ratios for cardiovascular and overall death in patients of the lowest CETP quartile, but no association between CETP plasma levels and blood pressure or aldosterone levels (data not shown). Therefore, our data strongly suggest that it was the low endogenous CETP plasma levels per se rather than an increase in blood pressure and aldosterone levels causing the untoward results in the ILLUMINATE trial.

Our study clearly demonstrates for the first time that low endogenous CETP plasma levels constitute an independent risk factor for all-cause and cardiovascular mortality. In light of this result it could appear unjustified to pharmacologically inhibit CETP activity in subjects already at risk because of low activity of CETP. Future directions for research in HDL-targeted interventions will have to focus on HDL function rather than on mere HDL plasma levels.


Cholesteryl ester transfer protein is the major player in reverse cholesterol transport but its role in the development of atherosclerosis continues to be in question since its discovery nearly 20 years ago. Following the ahead-of-schedule termination of the large phase III clinical trial ILLUMINATE of the CETP inhibitor torcetrapib the dispute reached a fervent revival. The authors of the ILLUMINATE trial proposed two explanations for the higher mortality in the torcetrapib group, i.e., a side-effect of the drug (increased blood pressure, etc.) or suppressed CETP activity per se. In the work submitted herein we present a large prospective observation on a very similar study population relating variation of CETP mass to mortality. Our data suggest that endogenous low CETP plasma levels constitute an independent risk factor for all-cause and cardiovascular mortality and, thus, are strongly pointing to the latter explanation for the ILLUMINATE results, i.e., CETP inhibition per se causing increased mortality. We believe that our study provides a serious caveat to CETP inhibition in general.


Funding sources

This work was supported by the Medizinische Forschungsfoerderung Innsbruck (MFI No. 4316 to I.T.), by the Jubilaeumsfond der Oesterreichischen Nationalbank (OENB, No. 12156 to I.T. and A.R.), and by the Fonds zur Foerderung der wissenschaftlichen Forschung (FWF, P19999-B05 to A.R.).


Conflict of Interest Disclosures



1. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255–1274. [PubMed]
2. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov. 2008;7:143–155. [PubMed]
3. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–1515. [PubMed]
4. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–1630. [PubMed]
5. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122. [PubMed]
6. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316. [PubMed]
7. Olsson AG. Is high HDL cholesterol always good? Ann Med. 2008;41:11–18. [PubMed]
8. Rader DJ. Illuminating HDL--is it still a viable therapeutic target? N Engl J Med. 2007;357:2180–2183. [PubMed]
9. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2:S1–73. [PubMed]
10. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(Suppl 1):S43–S48. [PubMed]
11. Ritsch A, Auer B, Foger B, Schwarz S, Patsch JR. Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res. 1993;34:673–679. [PubMed]
12. Ritsch A, Ebenbichler C, Naschberger E, Schgoer W, Stanzl U, Dietrich H, Heinrich PC, Saito K, Patsch JR. Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clin Chem Lab Med. 2004;42:247–255. [PubMed]
13. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. Jama. 2008;299:2777–2788. [PubMed]
14. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199–2211. [PMC free article] [PubMed]
15. Föger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:1430–1436. [PubMed]
16. Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 2008;28:1890–1891. [PubMed]
17. Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest. 2008;118:364–375. [PMC free article] [PubMed]
18. Cazita PM, Barbeiro DF, Moretti AI, Quintao EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008;30:590–595. [PubMed]
19. Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med. 2006;260:151–159. [PubMed]
20. Ritsch A, Patsch JR. Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Curr Opin Lipidol. 2003;14:173–179. [PubMed]
21. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917–2923. [PMC free article] [PubMed]